This study aims to compare the safety and curative effect of
celecoxib and small-dose
methylprednisolone sodium succinate in patients with
peptic ulcer hemorrhage combined with acute
gout. In this randomized, controlled trial, a total of 136 patients with
peptic ulcer hemorrhage combined with acute
gout were divided into the
celecoxib group or the small-dose
methylprednisolone sodium succinate group. These patients underwent gastroscopy hemostasis and
proton pump inhibitor (PPI)
therapy. Moreover, for the treatment of
gout, the patients were administered either
celecoxib or small-dose
methylprednisolone sodium succinate. Adverse reactions and the visual analogue scale (VAS) score were recorded for the two groups. The difference in adverse reactions between the two groups was not significant (χ(2) = 0.002, P = 0.967). The duration of evident
pain relief after the first dose of treatment showed a significant difference between the two groups (t = 13.728, P < 0.01). The VAS scores before treatment were not significantly different between the two groups (t = -1.786, P = 0.076). The VAS scores at 6 h, 2 days, 4 days, 6 days, and 8 days
after treatment were significantly different between the two groups (t = 3.239, 6.586, 6.280, 3.737, 3.215; P = 0.002, 0.000, 0.000, 0.000, 0.002, respectively). In cases that receive effective gastroscopy hemostasis and PPI
therapy, small-dose
methylprednisolone sodium succinate exhibits a greater clinical curative effect for
peptic ulcer hemorrhage combined with acute
gout as compared to
celecoxib, and is associated with greater safety.